
Danyelza Added to NCCN Guidelines for High-Risk Neuroblastoma
Danyelza is now recommended by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a NCCN category 2a treatment option for patients with high-risk neuroblastoma, a type of brain cancer, according to a news release …